Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$2.17 USD
-0.06 (-2.69%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Corvus Pharmaceuticals, Inc. [CRVS]
Reports for Purchase
Showing records 41 - 60 ( 154 total )
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CPI-006 Moving Into Spotlight; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
3Q20 - Multiple Catalysts for the Rest of 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; SITC COVID and ASH PTCL Data Ahead
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
EVENT: COVID-19 Therapeutics in Development: Beyond Gilead, Regeneron and Lilly
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Two Companies Presenting at Our Virtual COVID Therapeutics Conference
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Expanding into China; Higher $12 PT; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
CPI-006 Continues to Look Like an Angel Against COVID-19
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Data from the MORPHEUS Study in Lung Cancer at ESMO
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initial Data from CPI-006 COVID-19 Study Supports Advancement
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
2Q20: The Second Half of 2020 Is Rich with Data
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; Gaining Momentum with Catalyst Heavy 2H:2020
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R